Adherence and Growth Outcomes in a Large Cohort of Children Treated With Recombinant GH Using a Connected Auto-injector
Year: 2025
Type: article
Study design: Observational Study
Abstract: Context: Adherence to recombinant GH treatment is crucial to achieve optimal adult height in children with growth disorders. Information on factors responsible for differences in adherence and growth in different countries is limited. Aim: To evaluate adherence and catch-up growth in children receiving GH using Easypod® auto-injectors. Methods: Retrospective cohort analysis of adherence and height, from 481 children (55% boys) in 19 centers in France, from the Growzen® Connect database, from mid-2018 to end-2023. Adherence was classified as high (≥85% of injections) or medium/low (<85%). Gain in height SD score (HSDS) was evaluated after 1 and 2 years of GH treatment. Results: = .030). Conclusion: Children using Easypod exhibit high adherence, which aids clinical decision-making and patient engagement. Adherence and catch-up growth decrease with age. Indication for GH treatment had little impact, but overall catch-up growth was significantly greater with high adherence.
Source: Journal of the Endocrine Society
Institutions: Hôpital Necker-Enfants Malades, Inserm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Centre Hospitalier Universitaire d'Angers, Netherlands Organisation for Applied Scientific Research, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Cemka-Eval (France), Centre Hospitalier Universitaire de Toulouse, Université Paris-Saclay, Bicêtre Hospital
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,255
Funder: Merck KGaA
Awards: G1670422463, G490769284
OpenAlex ID: W4415502894